LeonaBio (LONA) Cash & Equivalents (2019 - 2026)

LeonaBio (LONA) has 8 years of Cash & Equivalents data on file, last reported at $32.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 24.26% year-over-year to $32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (up 24.26% YoY) and the FY2025 annual result came in at $69.3 million, up 43.02% from the prior year.
• Cash & Equivalents slipped to $32.8 million in Q1 2026 per LONA's latest filing, from $69.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $117.8 million in Q1 2022 and bottomed at $19.9 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $77.8 million (2024), against an average of $73.8 million.
• Peak annual rise in Cash & Equivalents reached 43.02% in 2025, while the deepest fall reached 73.06% in 2025.
• Tracing LONA's Cash & Equivalents over 5 years: stood at $96.0 million in 2022, then declined by 5.61% to $90.6 million in 2023, then slumped by 46.53% to $48.4 million in 2024, then jumped by 43.02% to $69.3 million in 2025, then plunged by 52.61% to $32.8 million in 2026.
• Per Business Quant, the three latest LONA Cash & Equivalents figures stand at $32.8 million (Q1 2026), $69.3 million (Q4 2025), and $20.9 million (Q3 2025).

Peer Comparison